CS MEDICA Achieves Fourth European Patent with Psoriasis Gel

Strengthening Competitive Edge and Driving Innovation

CS MEDICA announces the achievement of its fourth European patent, this time for its Psoriasis Gel, which is already MDR-approved. This milestone underscores the company’s dedication to delivering innovative, science-backed treatments and further solidifies its competitive edge in the MedTech sector.

The patent reinforces CS MEDICA’s market position and elevates the company’s value as an innovative player in the MedTech industry, proving its resilience and commitment to growth despite challenges faced as a scale-up company.

For more information, visit cs-medica.com

For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@cs-medica.com
Website: https://www.cs-medica.com/

 

About CS MEDICA A/S
Founded in 2011, CS MEDICA is a Danish MedTech company specializing in CBD-infused treatments for autoimmune and stress-related conditions, including arthritis, psoriasis, sleep, and pain management. Operating at the intersection of the pharmaceutical and cosmetics industries, CS MEDICA delivers clinically supported products with fewer side effects, offering competitive and accessible alternatives. With regulated products, cutting-edge R&D, and the benefits of CBD, the company provides innovative, safe, and effective solutions. Its capital-light business model and trusted European production partners further enhance its ability to offer high-quality treatments, setting CS MEDICA apart in the MedTech as well as the CBD sector.

Tags: